AP 026
Alternative Names: AP-026; TQA-2226Latest Information Update: 16 Jan 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical; Sino Biopharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Recombinant fusion proteins
- Mechanism of Action Fibroblast growth factor 21 modulators; Glucagon-like peptide 1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 28 Nov 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis (Injection), prior to November 2023 (Sino Biopharmaceuticals website, November 2023)
- 24 May 2023 Phase-I clinical trials in Type 2 diabetes mellitus (In adults) in China (Injection) (NCT06143423)